JP5528657B2 - 酸化還元電位水溶液並びにその製造方法および使用方法 - Google Patents
酸化還元電位水溶液並びにその製造方法および使用方法 Download PDFInfo
- Publication number
- JP5528657B2 JP5528657B2 JP2006547576A JP2006547576A JP5528657B2 JP 5528657 B2 JP5528657 B2 JP 5528657B2 JP 2006547576 A JP2006547576 A JP 2006547576A JP 2006547576 A JP2006547576 A JP 2006547576A JP 5528657 B2 JP5528657 B2 JP 5528657B2
- Authority
- JP
- Japan
- Prior art keywords
- solution
- chamber
- redox potential
- anode
- cathode
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007864 aqueous solution Substances 0.000 title claims description 59
- 238000004519 manufacturing process Methods 0.000 title claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 355
- 239000000243 solution Substances 0.000 claims description 303
- 239000000203 mixture Substances 0.000 claims description 121
- 238000009472 formulation Methods 0.000 claims description 101
- 239000012266 salt solution Substances 0.000 claims description 90
- 238000000034 method Methods 0.000 claims description 88
- 239000000460 chlorine Substances 0.000 claims description 59
- 210000001519 tissue Anatomy 0.000 claims description 56
- 239000003795 chemical substances by application Substances 0.000 claims description 53
- 238000005868 electrolysis reaction Methods 0.000 claims description 50
- 229910052801 chlorine Inorganic materials 0.000 claims description 49
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 48
- 239000002562 thickening agent Substances 0.000 claims description 43
- 238000011282 treatment Methods 0.000 claims description 35
- 241000894006 Bacteria Species 0.000 claims description 33
- 208000015181 infectious disease Diseases 0.000 claims description 28
- 241000700605 Viruses Species 0.000 claims description 24
- 239000000499 gel Substances 0.000 claims description 24
- 210000004379 membrane Anatomy 0.000 claims description 24
- 239000012528 membrane Substances 0.000 claims description 24
- 230000003472 neutralizing effect Effects 0.000 claims description 24
- 241000233866 Fungi Species 0.000 claims description 23
- 238000001356 surgical procedure Methods 0.000 claims description 23
- -1 peroxide Hydrogen Chemical class 0.000 claims description 21
- 244000005700 microbiome Species 0.000 claims description 20
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 claims description 19
- 239000000645 desinfectant Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 15
- 230000002829 reductive effect Effects 0.000 claims description 14
- 239000000523 sample Substances 0.000 claims description 14
- 238000011200 topical administration Methods 0.000 claims description 14
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 13
- 241000588724 Escherichia coli Species 0.000 claims description 11
- 239000005708 Sodium hypochlorite Substances 0.000 claims description 11
- 241000222122 Candida albicans Species 0.000 claims description 10
- 229940095731 candida albicans Drugs 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 241000295644 Staphylococcaceae Species 0.000 claims description 9
- 238000000889 atomisation Methods 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 9
- 238000012387 aerosolization Methods 0.000 claims description 8
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000002663 nebulization Methods 0.000 claims description 7
- 230000000241 respiratory effect Effects 0.000 claims description 7
- 208000025865 Ulcer Diseases 0.000 claims description 6
- 231100000397 ulcer Toxicity 0.000 claims description 6
- 230000029663 wound healing Effects 0.000 claims description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 5
- 210000004400 mucous membrane Anatomy 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 244000063299 Bacillus subtilis Species 0.000 claims description 4
- 241000709661 Enterovirus Species 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 210000002345 respiratory system Anatomy 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 208000010201 Exanthema Diseases 0.000 claims description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 3
- 238000005299 abrasion Methods 0.000 claims description 3
- 230000002924 anti-infective effect Effects 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 201000005884 exanthem Diseases 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 210000000214 mouth Anatomy 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 206010037844 rash Diseases 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 210000000683 abdominal cavity Anatomy 0.000 claims description 2
- 238000002266 amputation Methods 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 210000000115 thoracic cavity Anatomy 0.000 claims description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims 6
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 2
- 241000228245 Aspergillus niger Species 0.000 claims 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 1
- 241000195493 Cryptophyta Species 0.000 claims 1
- 208000002847 Surgical Wound Diseases 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 230000033116 oxidation-reduction process Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 43
- 239000000758 substrate Substances 0.000 description 39
- 239000007844 bleaching agent Substances 0.000 description 35
- 208000027418 Wounds and injury Diseases 0.000 description 32
- 206010052428 Wound Diseases 0.000 description 30
- 229920000642 polymer Polymers 0.000 description 29
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 27
- 241000894007 species Species 0.000 description 25
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000000463 material Substances 0.000 description 21
- 229920002125 Sokalan® Polymers 0.000 description 20
- 210000003491 skin Anatomy 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 238000004140 cleaning Methods 0.000 description 17
- 201000007100 Pharyngitis Diseases 0.000 description 16
- 238000006722 reduction reaction Methods 0.000 description 16
- 238000004659 sterilization and disinfection Methods 0.000 description 16
- 229940088710 antibiotic agent Drugs 0.000 description 14
- 239000007789 gas Substances 0.000 description 14
- 238000002156 mixing Methods 0.000 description 14
- 230000009467 reduction Effects 0.000 description 14
- 239000003242 anti bacterial agent Substances 0.000 description 13
- 239000004744 fabric Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 239000004155 Chlorine dioxide Substances 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 239000013566 allergen Substances 0.000 description 11
- 235000019398 chlorine dioxide Nutrition 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 10
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 10
- 239000003014 ion exchange membrane Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 9
- 206010009137 Chronic sinusitis Diseases 0.000 description 9
- 239000000443 aerosol Substances 0.000 description 9
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 8
- 230000002411 adverse Effects 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 201000009890 sinusitis Diseases 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 230000000249 desinfective effect Effects 0.000 description 7
- 210000000981 epithelium Anatomy 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 150000002978 peroxides Chemical class 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 208000008960 Diabetic foot Diseases 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 208000016150 acute pharyngitis Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000002850 nasal mucosa Anatomy 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 229910001415 sodium ion Inorganic materials 0.000 description 6
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 5
- 206010072369 Pharyngeal exudate Diseases 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 206010001093 acute tonsillitis Diseases 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 230000003434 inspiratory effect Effects 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 4
- 206010015946 Eye irritation Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 238000011888 autopsy Methods 0.000 description 4
- 230000000721 bacterilogical effect Effects 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 238000004061 bleaching Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 231100000013 eye irritation Toxicity 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- 229920001903 high density polyethylene Polymers 0.000 description 4
- 239000004700 high-density polyethylene Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000006199 nebulizer Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 206010044008 tonsillitis Diseases 0.000 description 4
- 206010001076 Acute sinusitis Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
- 208000001840 Dandruff Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229920000297 Rayon Polymers 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000012459 cleaning agent Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- UQSQSQZYBQSBJZ-UHFFFAOYSA-N fluorosulfonic acid Chemical compound OS(F)(=O)=O UQSQSQZYBQSBJZ-UHFFFAOYSA-N 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002262 irrigation Effects 0.000 description 3
- 238000003973 irrigation Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000012209 synthetic fiber Substances 0.000 description 3
- 229920002994 synthetic fiber Polymers 0.000 description 3
- 231100000057 systemic toxicity Toxicity 0.000 description 3
- 231100000041 toxicology testing Toxicity 0.000 description 3
- 230000003253 viricidal effect Effects 0.000 description 3
- RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 229910019093 NaOCl Inorganic materials 0.000 description 2
- 208000000592 Nasal Polyps Diseases 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- 206010034839 Pharyngitis streptococcal Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 206010044013 Tonsillitis streptococcal Diseases 0.000 description 2
- 231100000921 acute inhalation toxicity Toxicity 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000002800 charge carrier Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 229960002626 clarithromycin Drugs 0.000 description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000005202 decontamination Methods 0.000 description 2
- 230000003588 decontaminative effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 208000019258 ear infection Diseases 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229920002313 fluoropolymer Polymers 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 206010033072 otitis externa Diseases 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 235000021118 plant-derived protein Nutrition 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 206010047470 viral myocarditis Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- QNGVNLMMEQUVQK-UHFFFAOYSA-N 4-n,4-n-diethylbenzene-1,4-diamine Chemical compound CCN(CC)C1=CC=C(N)C=C1 QNGVNLMMEQUVQK-UHFFFAOYSA-N 0.000 description 1
- CGLVZFOCZLHKOH-UHFFFAOYSA-N 8,18-dichloro-5,15-diethyl-5,15-dihydrodiindolo(3,2-b:3',2'-m)triphenodioxazine Chemical compound CCN1C2=CC=CC=C2C2=C1C=C1OC3=C(Cl)C4=NC(C=C5C6=CC=CC=C6N(C5=C5)CC)=C5OC4=C(Cl)C3=NC1=C2 CGLVZFOCZLHKOH-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical class [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- XYTLGPGQNITDJP-UHFFFAOYSA-N C(C=C)(=O)O.C(C=C)(=O)O.OCCNC1=CC=CC=2C(C3=CC=CC=C3C(C12)=O)=O Chemical compound C(C=C)(=O)O.C(C=C)(=O)O.OCCNC1=CC=CC=2C(C3=CC=CC=C3C(C12)=O)=O XYTLGPGQNITDJP-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- RUPBZQFQVRMKDG-UHFFFAOYSA-M Didecyldimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC RUPBZQFQVRMKDG-UHFFFAOYSA-M 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000726740 Homo sapiens Homeobox protein cut-like 1 Proteins 0.000 description 1
- 101000761460 Homo sapiens Protein CASP Proteins 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 229920010126 Linear Low Density Polyethylene (LLDPE) Polymers 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 206010036303 Post streptococcal glomerulonephritis Diseases 0.000 description 1
- 208000037486 Postoperative Hemorrhage Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100024933 Protein CASP Human genes 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 229920001131 Pulp (paper) Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 231100000109 acute inhalation LD50 Toxicity 0.000 description 1
- 230000008578 acute process Effects 0.000 description 1
- 201000005638 acute proliferative glomerulonephritis Diseases 0.000 description 1
- 231100000293 acute skin toxicity Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000013572 airborne allergen Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229940086737 allyl sucrose Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000011902 cervical lymphadenopathy Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-M chlorate Inorganic materials [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- MAYPHUUCLRDEAZ-UHFFFAOYSA-N chlorine peroxide Inorganic materials ClOOCl MAYPHUUCLRDEAZ-UHFFFAOYSA-N 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-M chlorite Chemical compound [O-]Cl=O QBWCMBCROVPCKQ-UHFFFAOYSA-M 0.000 description 1
- 229940005993 chlorite ion Drugs 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 210000002895 cranial sinus Anatomy 0.000 description 1
- 150000001925 cycloalkenes Chemical class 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000000804 electron spin resonance spectroscopy Methods 0.000 description 1
- 238000013129 endoscopic sinus surgery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 231100000016 inhalation toxicity Toxicity 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- LWXVCCOAQYNXNX-UHFFFAOYSA-N lithium hypochlorite Chemical compound [Li+].Cl[O-] LWXVCCOAQYNXNX-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- YZQBYALVHAANGI-UHFFFAOYSA-N magnesium;dihypochlorite Chemical compound [Mg+2].Cl[O-].Cl[O-] YZQBYALVHAANGI-UHFFFAOYSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000492 nasalseptum Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001869 rapid Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 231100000130 skin irritation / corrosion testing Toxicity 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 239000008234 soft water Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 230000003330 sporicidal effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
- A61L2/186—Peroxide solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
- C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
- C02F1/46104—Devices therefor; Their operating or servicing
- C02F1/4618—Devices therefor; Their operating or servicing for producing "ionised" acidic or basic water
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/24—Medical instruments, e.g. endoscopes, catheters, sharps
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
- C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
- C02F1/467—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction
- C02F1/4672—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction by electrooxydation
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/72—Treatment of water, waste water, or sewage by oxidation
- C02F1/722—Oxidation by peroxides
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/72—Treatment of water, waste water, or sewage by oxidation
- C02F1/76—Treatment of water, waste water, or sewage by oxidation with halogens or compounds of halogens
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
- C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
- C02F1/46104—Devices therefor; Their operating or servicing
- C02F1/4618—Devices therefor; Their operating or servicing for producing "ionised" acidic or basic water
- C02F2001/46195—Devices therefor; Their operating or servicing for producing "ionised" acidic or basic water characterised by the oxidation reduction potential [ORP]
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
- C02F2103/02—Non-contaminated water, e.g. for industrial water supply
- C02F2103/026—Treating water for medical or cosmetic purposes
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2201/00—Apparatus for treatment of water, waste water or sewage
- C02F2201/46—Apparatus for electrochemical processes
- C02F2201/461—Electrolysis apparatus
- C02F2201/46105—Details relating to the electrolytic devices
- C02F2201/46115—Electrolytic cell with membranes or diaphragms
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2209/00—Controlling or monitoring parameters in water treatment
- C02F2209/04—Oxidation reduction potential [ORP]
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2209/00—Controlling or monitoring parameters in water treatment
- C02F2209/06—Controlling or monitoring parameters in water treatment pH
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2209/00—Controlling or monitoring parameters in water treatment
- C02F2209/40—Liquid flow rate
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2303/00—Specific treatment goals
- C02F2303/04—Disinfection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- AIDS & HIV (AREA)
- Hydrology & Water Resources (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Electrochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Environmental & Geological Engineering (AREA)
- Water Supply & Treatment (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Water Treatment By Electricity Or Magnetism (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
Description
少なくとも2つの電解セルを提供すること、ここで、各セルは、アノードチャンバー、カソードチャンバー、およびアノードチャンバーとカソードチャンバーとの間に位置する塩溶液チャンバーを有し、アノードチャンバーは、アノード電極と第1膜とによって塩溶液チャンバーから分離されており、そしてカソードチャンバーは、カソード電極と第2膜とによって塩溶液チャンバーから分離されている;
アノードチャンバーとカソードチャンバーとを通る水の流れを供給すること;
塩溶液チャンバーを通る塩溶液の流れを供給すること;
アノードチャンバーとカソードチャンバーとを通る水の流れ、および塩溶液チャンバーを通る塩溶液の流れと同時に、アノード電極とカソード電極とに電流を供給すること;および
電解セルによって生成した酸化還元電位水溶液を集めること;
を包含する。
少なくとも1つの電解セルを提供すること、ここで、当該セルは、アノードチャンバー、カソードチャンバー、およびアノードチャンバーとカソードチャンバーとの間に位置する塩溶液チャンバーを有し、アノードチャンバーは、アノード電極と第1膜とによって塩溶液チャンバーから分離されており、そしてカソードチャンバーは、カソード電極と第2膜とによって塩溶液チャンバーから分離されている;
アノードチャンバーとカソードチャンバーとを通る水の流れを供給すること;
塩溶液チャンバーを通る塩溶液の流れを供給すること;
アノードチャンバーとカソードチャンバーとを通る水の流れ、および塩溶液チャンバーを通る塩溶液の流れと同時に、アノード電極とカソード電極とに電流を供給すること;および
電解セルによって生成した酸化還元電位水を集めること
を包含する。
本発明は、患者の病状を予防または治療する方法を提供する。該方法は、治療有効量の酸化還元電位(ORP)水溶液を患者に投与することを含み、この溶液は少なくとも24時間安定である。病状としては、例えば、医学的病状、疾患、負傷、アレルギーなどを挙げることができ、これらは本発明のORP水溶液で治療可能である。
これらの実施例は、本発明のORP水溶液の独自の特徴を示す。実施例1−3のORP水溶液のサンプルは、本明細書に記載の方法に基づいて分析し、各サンプルに存在するイオン種および他の化学種の物理的特性およびレベルを決定した。ORP水溶液の各サンプルについて、pH、酸化還元電位(ORP)および存在するイオン種を表1に示す。
これらの実施例は、本発明のORP水溶液への種々の量の漂白剤の添加を示す。特に、
これらの実施例は、組成物の抗微生物活性および織物漂白能力を示す。
本実施例は、本発明のORP水溶液の毒性プロフィールに関する。本発明の代表的ORP水溶液であるMicrosyn60(即ちM60)をこれらの研究で用いた。
本実施例は、ORP水又はゲル形態のORP水を使用する場合、口腔法及び上顎顔面法で直面する血液損失の減少を記載する。
本実施例は、咽頭炎治療について本発明のORP水溶液の有効性を決定するために使用できる臨床研究を示す。
本実施例は、患者への局所投与に適した本発明の製剤を提供する。該製剤は以下を含有する。
成分 量
ORP水溶液 250mL
Carbopol(登録商標)ポリマー粉末(増粘剤) 15g
トリエタノールアミン(中和剤) 80mL
本実施例は、患者への局所投与に適した本発明の製剤を提供する。該製剤は以下を含有する。
成分 量
ORP水溶液 1000mL
Carbopol(登録商標)ポリマー粉末(増粘剤) 15g
トリエタノールアミン(中和剤) 80mL
本実施例は、患者への局所投与に適した本発明の製剤を提供する。該製剤は以下を含有する。
成分 量
ORP水溶液 250mL
Carbopol(登録商標)ポリマー粉末(増粘剤) 7g
トリエタノールアミン(中和剤) 12mL
本実施例は、ORP水溶液と増粘剤とを含有する本発明の製剤の製造を記載する。
本実施例は、糖尿病性の足の潰瘍の治療のための、本発明のゲル製剤の使用を記載する。
Claims (52)
- pHが7.4〜7.6であり、全塩素含量が50ppm〜200ppmであり、かつ、溶液の製造後少なくとも2ケ月で測定したとき、1分間の曝露後に生物サンプルの全生物濃度を少なくとも4log(104 )減少させることができる、25ppm〜50ppmの次亜塩素酸ナトリウムおよび15ppm〜35ppmの次亜塩素酸を含有する酸化還元電位水溶液であって、
当該酸化還元電位水溶液が、電解セルのアノードチャンバーおよびカソードチャンバーを通る水の流れを可能にし、および塩溶液チャンバーを通る塩溶液の流れを可能にし、同時にアノード電極とカソード電極とに電流を供給し、酸化還元電位水溶液を得ることを含むプロセスによって得られ、
ここで、該電解セルにおいて、(i)該塩溶液チャンバーが該アノードチャンバーと該カソードチャンバーとの間に位置しており、(ii)該アノードチャンバーが、アノード電極と第1膜とによって該塩溶液チャンバーから分離されており、かつ、(iii)該カソードチャンバーが、カソード電極と第2膜とによって該塩溶液チャンバーから分離されている、
前記酸化還元電位水溶液。 - 溶液の製造後少なくとも2ケ月で測定したとき、1分間の曝露後に生物サンプルの全生物濃度を少なくとも6log(106 )減少させることができる、請求項1に記載の溶液。
- 酸化還元電位水溶液の製造後少なくとも2ケ月で測定したとき、1分以内の曝露で、大腸菌、緑濃菌、ブドウ球菌およびカンジダ・アルビカンスからなる群から選択される生きた微生物のサンプルの微生物濃度を少なくとも6log(106 )減少させることができる、請求項2に記載の溶液。
- 溶液の製造後少なくとも2ケ月で測定したとき、1分以内の曝露で、1×106と1×108微生物/mlとの間の初期濃度を有する大腸菌、緑濃菌、ブドウ球菌およびカンジダ・アルビカンスからなる群から選択される生きた微生物のサンプルを、0微生物/mlの最終濃度にまで減少させうる、請求項1に記載の溶液。
- 溶液の製造後少なくとも2ケ月で測定したとき、30秒以内の曝露で、バチルス・アスロフェウス胞子の懸濁液の胞子濃度を少なくとも4log(104 )減少させることができる、請求項1に記載の溶液。
- 溶液の製造後少なくとも2ケ月で測定したとき、10分以内の曝露で、アスペルギルス・ニガー胞子の懸濁液の胞子濃度を少なくとも4log(104 )減少させることができる、請求項1に記載の溶液。
- 請求項1〜6の1項に記載の酸化還元電位水溶液を含む、密封容器。
- 酸化還元電位水溶液を製造する方法であって、当該方法が、
(a)少なくとも1つの電解セルを提供することを含み、ここで、該セルが、アノードチャンバー、カソードチャンバー、およびアノードチャンバーとカソードチャンバーとの間に位置する塩溶液チャンバーを有し、ここで、アノードチャンバーが、アノード電極と第1膜とによって塩溶液チャンバーから分離されており、かつ、カソードチャンバーが、カソード電極と第2膜とによって塩溶液チャンバーから分離されており;
(b)アノードチャンバーおよびカソードチャンバーを通る水の流れを供給することを含み;
(c)塩溶液チャンバーを通る塩溶液の流れを供給することを含み;
(d)工程(b)および(c)と同時に、アノード電極とカソード電極とに電流を供給することを含み;および
(e)電解セルによって生成した酸化還元電位水溶液を集めることを含み、ここで、該酸化還元電位水溶液がアノード水とカソード水とを含み、該酸化還元電位水溶液のpHが7.4〜7.6であり、該酸化還元電位水溶液の全塩素含量が50ppm〜200ppmであり、該酸化還元電位水溶液が25ppm〜50ppmの次亜塩素酸ナトリウムおよび15ppm〜35ppmの次亜塩素酸を含有し、
ここで、該酸化還元電位水溶液が、製造後少なくとも2ケ月で測定したとき、1分間の曝露後に生物サンプルの全生物濃度を少なくとも4log(104 )減少させることができる、
前記方法。 - 酸化還元電位水溶液が、10体積%〜50体積%の量のカソード水を含む、請求項8に記載の方法。
- 酸化還元電位水溶液が、該溶液の20体積%〜40体積%の量のカソード水を含む、請求項9に記載の方法。
- 酸化還元電位水溶液が、該溶液の50体積%〜90体積%の量のアノード水を含む、請求項8に記載の方法。
- 過酸化水素を含む酸化還元電位水溶液であって、当該酸化還元電位水溶液のpHが7.4〜7.6であり、かつ、当該酸化還元電位水溶液が、当該酸化還元電位水溶液の製造後少なくとも2ケ月で測定したとき、1分間の曝露後に生物サンプルの全生物濃度を少なくとも4log(104 )減少させることができ、当該酸化還元電位水溶液の全塩素含量が50ppm〜200ppmであり、当該酸化還元電位水溶液が25ppm〜50ppmの次亜塩素酸ナトリウムおよび15ppm〜35ppmの次亜塩素酸を含有し、
ここで、当該酸化還元電位水溶液が、電解セルのアノードチャンバーおよびカソードチャンバーを通る水の流れを可能にし、および塩溶液チャンバーを通る塩溶液の流れを可能にし、同時にアノード電極とカソード電極とに電流を供給し、酸化還元電位水溶液を得ることを含むプロセスによって得られ、
ここで、該電解セルにおいて、(i)該塩溶液チャンバーが該アノードチャンバーと該カソードチャンバーとの間に位置しており、(ii)該アノードチャンバーが、アノード電極と第1膜とによって該塩溶液チャンバーから分離されており、かつ、(iii)該カソードチャンバーが、カソード電極と第2膜とによって該塩溶液チャンバーから分離されている、
前記酸化還元電位水溶液。 - 治療有効量の請求項1〜6および12のいずれかに記載の酸化還元電位水溶液を含有する、患者の病状の予防または治療剤。
- 病状が呼吸器系の病状であり、溶液が上気道に投与される、請求項13に記載の剤。
- 溶液が蒸気または噴霧として投与される、請求項13に記載の剤。
- 溶液が、エアロゾル化、噴霧化または微粒化によって投与される、請求項14に記載の剤。
- 溶液が、1ミクロン〜10ミクロンの範囲の直径を有する小滴の形態で投与される、請求項16に記載の剤。
- 病状が、ウイルス、細菌、および真菌からなる群から選択される1種以上の微生物による感染症である、請求項13に記載の剤。
- 1種以上のウイルスが、アデノウイルス、HIV、ライノウイルス、およびインフルエンザウイルスからなる群から選択される、請求項18に記載の剤。
- 1種以上の細菌が、大腸菌、緑濃菌、ブドウ球菌およびヒト結核菌からなる群から選択される、請求項18に記載の剤。
- 1種以上の真菌が、カンジダ・アルビカンス、枯草菌およびバチルス・アスロフェウスからなる群から選択される、請求項18に記載の剤。
- 病状が炎症性の病状である、請求項13に記載の剤。
- 治療有効量の請求項1〜6または12のいずれかに記載の酸化還元電位水溶液を含有する、正常に機能しないかまたは損傷している組織の治療剤。
- 組織を溶液で灌注することを含む、請求項23に記載の剤。
- 溶液を蒸気または噴霧として組織に投与することを含む、請求項23に記載の剤。
- 溶液を、エアロゾル化、噴霧化または微粒化によって組織に投与することを含む、請求項23に記載の剤。
- 組織が、手術によって正常に機能しないかまたは損傷している、請求項23に記載の剤。
- 組織が、外科的切開、口腔手術、グラフト手術、インプラント手術、トランスプラント手術、焼灼、切断、放射線、化学療法またはそれらの組み合わせによって、正常に機能しないかまたは損傷している、請求項27に記載の剤。
- 組織が、熱傷、切り傷、擦り傷、掻き傷、発疹、潰瘍、刺し傷またはそれらの組み合わせによって、正常に機能しないかまたは損傷している、請求項23に記載の剤。
- 正常に機能しないかまたは損傷している組織が感染している、請求項23に記載の剤。
- 感染が、ウイルス、細菌、真菌およびそれらの組み合わせからなる群から選択される1種以上の微生物によるものである、請求項30に記載の剤。
- 1種以上のウイルスが、アデノウイルス、HIV、ライノウイルスおよびインフルエンザウイルスから選択される、請求項31に記載の剤。
- 1種以上の細菌が、大腸菌、緑濃菌、ブドウ球菌、ヒト結核菌からなる群から選択される、請求項31に記載の剤。
- 1種以上の真菌が、カンジダ・アルビカンス、枯草菌およびバチルス・アスロフェウスからなる群から選択される、請求項31に記載の剤。
- 抗感染量の請求項1〜6または12のいずれかに記載の酸化還元電位水溶液を含有する、生物学的な組織の消毒剤。
- 生物学的な組織を溶液で灌注することを含む、請求項35に記載の剤。
- 生物学的な組織を蒸気または噴霧の形態の溶液と接触させることを含む、請求項35に記載の剤。
- 生物学的な組織を、エアロゾル化、噴霧化または微粒化によって溶液と接触させることを含む、請求項36に記載の剤。
- 生物学的な組織が1種以上の体腔内の組織を含む、請求項35に記載の剤。
- 生物学的な組織が、口腔、副鼻腔、頭蓋腔、腹腔または胸腔内にある、請求項39に記載の剤。
- 生物学的な組織が、筋肉組織、骨組織、器官組織、粘膜組織およびそれらの組み合わせからなる群から選択される、請求項35に記載の剤。
- 酸化還元電位水溶液および増粘剤を含む局所投与用製剤であって、当該製剤のpHが7.4と7.6との間であり、該溶液の全塩素含量が50ppm〜200ppmであり、該溶液が25ppm〜50ppmの次亜塩素酸ナトリウムおよび15ppm〜35ppmの次亜塩素酸を含有し、かつ、当該製剤が、該溶液の製造後少なくとも2ケ月で測定したとき、1分間の曝露後に生物サンプルの全生物濃度を少なくとも4log(104 )減少させることができ、
ここで、該酸化還元電位水溶液が、電解セルのアノードチャンバーおよびカソードチャンバーを通る水の流れを可能にし、および塩溶液チャンバーを通る塩溶液の流れを可能にし、同時にアノード電極とカソード電極とに電流を供給し、酸化還元電位水溶液を得ることを含むプロセスによって得られ、
ここで、該電解セルにおいて、(i)該塩溶液チャンバーが該アノードチャンバーと該カソードチャンバーとの間に位置しており、(ii)該アノードチャンバーが、アノード電極と第1膜とによって該塩溶液チャンバーから分離されており、かつ、(iii)該カソードチャンバーが、カソード電極と第2膜とによって該塩溶液チャンバーから分離されている、
前記製剤。 - ローション、ゲル、クリーム、ペーストおよび軟膏からなる群から選択される、請求項42に記載の製剤。
- ゲルである、請求項43に記載の製剤。
- 10,000〜100,000cpsの粘度を有する、請求項43に記載の製剤。
- 増粘剤が、1mg/酸化還元電位水溶液250mL〜20mg/酸化還元電位水溶液250mLの量で存在する、請求項42に記載の製剤。
- 中和剤をさらに含む、請求項42に記載の製剤。
- 中和剤が、酸化還元電位水溶液の体積に基づいて3体積%〜35体積%の量で存在する、請求項47に記載の製剤。
- 酸化還元電位水溶液、1mg/酸化還元電位水溶液250mL〜20mg/酸化還元電位水溶液250mLの量の増粘剤、および酸化還元電位水溶液の体積に基づいて3体積%〜35体積%の量の中和剤を含む、患者に局所投与するためのゲル製剤であって、該製剤が7.4〜7.6のpHを有し、該溶液の全塩素含量が50ppm〜200ppmであり、該溶液が25ppm〜50ppmの次亜塩素酸ナトリウムおよび15ppm〜35ppmの次亜塩素酸を含有し、かつ、該製剤が、該溶液の製造後少なくとも2ケ月で測定したとき、1分間の曝露後に生物サンプルの全生物濃度を少なくとも4log(104 )減少させることができ、
ここで、該酸化還元電位水溶液が、電解セルのアノードチャンバーおよびカソードチャンバーを通る水の流れを可能にし、および塩溶液チャンバーを通る塩溶液の流れを可能にし、同時にアノード電極とカソード電極とに電流を供給し、酸化還元電位水溶液を得ることを含むプロセスによって得られ、
ここで、該電解セルにおいて、(i)該塩溶液チャンバーが該アノードチャンバーと該カソードチャンバーとの間に位置しており、(ii)該アノードチャンバーが、アノード電極と第1膜とによって該塩溶液チャンバーから分離されており、かつ、(iii)該カソードチャンバーが、カソード電極と第2膜とによって該塩溶液チャンバーから分離されている、
前記ゲル製剤。 - 請求項42〜48のいずれかに記載の局所投与用製剤と密封容器とを含む、薬学的投与形態。
- 患者の病状の治療または予防用である、請求項42〜48のいずれかに記載の製剤。
- 患者の創傷治癒の促進用である、請求項42〜48のいずれかに記載の製剤。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53358303P | 2003-12-30 | 2003-12-30 | |
US60/533,583 | 2003-12-30 | ||
US10/862,092 | 2004-06-04 | ||
US10/862,092 US20050139808A1 (en) | 2003-12-30 | 2004-06-04 | Oxidative reductive potential water solution and process for producing same |
US10/916,566 | 2004-08-11 | ||
US10/916,278 | 2004-08-11 | ||
US10/916,566 US9168318B2 (en) | 2003-12-30 | 2004-08-11 | Oxidative reductive potential water solution and methods of using the same |
US10/916,278 US20050196462A1 (en) | 2003-12-30 | 2004-08-11 | Topical formulation containing oxidative reductive potential water solution and method for using same |
PCT/US2004/043961 WO2005065383A2 (en) | 2003-12-30 | 2004-12-30 | Oxidative reductive potential water solution, processes for producing same and methods of using the same |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007517064A JP2007517064A (ja) | 2007-06-28 |
JP2007517064A5 JP2007517064A5 (ja) | 2008-02-21 |
JP5528657B2 true JP5528657B2 (ja) | 2014-06-25 |
Family
ID=34753897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006547576A Active JP5528657B2 (ja) | 2003-12-30 | 2004-12-30 | 酸化還元電位水溶液並びにその製造方法および使用方法 |
Country Status (7)
Country | Link |
---|---|
EP (2) | EP1702161A2 (ja) |
JP (1) | JP5528657B2 (ja) |
KR (1) | KR101249639B1 (ja) |
AU (1) | AU2004311432A1 (ja) |
CA (1) | CA2553943C (ja) |
MX (1) | MXPA05009960A (ja) |
WO (1) | WO2005065383A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2790976C1 (ru) * | 2021-12-07 | 2023-03-01 | Государственное Бюджетное Образовательное Учреждения Высшего Образования "Уральский Государственный Аграрный Университет" (ФГБОУ ВО Уральский ГАУ) | Способ содержания служебных собак |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1461474B1 (en) | 2001-12-05 | 2011-11-30 | Oculus Innovative Sciences, Inc. | Method and apparatus for producing negative and positive oxidative reductive potential (orp) water |
US9168318B2 (en) | 2003-12-30 | 2015-10-27 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and methods of using the same |
US8840873B2 (en) * | 2005-03-23 | 2014-09-23 | Oculus Innovative Sciences, Inc. | Method of treating second and third degree burns using oxidative reductive potential water solution |
EP1896043B1 (en) | 2005-05-02 | 2018-08-29 | Sonoma Pharmaceuticals, Inc. | Method of using oxidative reductive potential water solution in dental applications |
GB2429152A (en) * | 2005-08-19 | 2007-02-21 | Forum Bioscience Holdings Ltd | Electrochemically activated water for use as a virucide |
JP5060032B2 (ja) * | 2005-09-12 | 2012-10-31 | 株式会社ヒロマイト | 還元性水性組成物 |
AU2006307923B2 (en) | 2005-10-28 | 2012-02-02 | Akuatech S.R.L. | New highly stable aqueous solution, electrode with nanocoating for preparing the solution and method for making this electrode |
CN101405013A (zh) * | 2006-01-20 | 2009-04-08 | 奥古露丝创新科学公司 | 使用氧化还原电位水溶液治疗或预防腹膜炎的方法 |
CA2637175C (en) * | 2006-01-20 | 2015-07-14 | Oculus Innovative Sciences, Inc. | Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution |
GB2442519A (en) * | 2006-10-02 | 2008-04-09 | Forum Bioscience Holdings Ltd | Wound treatment compositions |
JP5313874B2 (ja) * | 2007-03-22 | 2013-10-09 | 大幸薬品株式会社 | アレルゲン不活性化剤 |
BRPI0810848B8 (pt) | 2007-04-25 | 2021-07-27 | Akuatech S R L | água eletrolítica altamente estável com largura de meia linha de rmn reduzida |
CA2702796A1 (en) * | 2007-10-23 | 2009-04-30 | Novozymes A/S | Methods for killing spores and disinfecting or sterilizing devices |
US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
SK50172008A3 (sk) * | 2008-02-20 | 2010-03-08 | Ľubomír Vozár | Ekologicky neškodlivý dezinfekčný prostriedok |
EP2376093B1 (en) * | 2008-12-22 | 2020-07-15 | Sonoma Pharmaceuticals, Inc. | Treating or preventing biofilm associated infections with free available chlorine water |
US10342825B2 (en) | 2009-06-15 | 2019-07-09 | Sonoma Pharmaceuticals, Inc. | Solution containing hypochlorous acid and methods of using same |
ES2549913T3 (es) | 2009-06-17 | 2015-11-03 | Apr Nanotechnologies S.A. | Métodos de tratamiento de trastornos oculares externos usando agua ácida de alto ORP y composiciones de la misma |
GB0912865D0 (en) * | 2009-07-23 | 2009-08-26 | Applied Chemistry Ltd | Endoscope decontamination system |
MX365380B (es) | 2009-07-30 | 2019-05-31 | Invekra S A P I De C V | Formulacion de hidrogel que comprende agua con ppotencial de oxidacion-reduccion. |
JP5831673B2 (ja) * | 2010-01-22 | 2015-12-09 | 東洋製罐株式会社 | 空間表面の殺菌方法 |
JP2011167665A (ja) * | 2010-02-22 | 2011-09-01 | Meiko Shoji Kk | アルカリイオン水スプレー装置 |
WO2011128682A2 (en) | 2010-04-14 | 2011-10-20 | Hypo-Stream Limited | Device for preparing dilute disinfectant solution |
US8641874B2 (en) * | 2010-12-09 | 2014-02-04 | Rayne Guest | Compact closed-loop electrolyzing process and apparatus |
US20120156307A1 (en) * | 2010-12-16 | 2012-06-21 | Apr Nanotechnologies S.A. | Medical uses of nanoclustered water |
US8882972B2 (en) | 2011-07-19 | 2014-11-11 | Ecolab Usa Inc | Support of ion exchange membranes |
US11478507B2 (en) | 2012-02-17 | 2022-10-25 | Wiab Water Innovation Ab | Compositions and methods for treating biofilms |
US11357794B2 (en) | 2012-02-17 | 2022-06-14 | Wiab Wafer Innovation Ab | Preparations for controlled-release of hypochlorous acid |
US11452741B2 (en) | 2012-02-17 | 2022-09-27 | Wiab Water Innovation Ab | Compositions and methods for treating transient biofilms |
US11484549B2 (en) | 2012-02-17 | 2022-11-01 | Wiab Water Innovation Ab | Compositions and methods for treating biofilms without inducing antimicrobial resistance |
US11364262B2 (en) | 2012-02-17 | 2022-06-21 | Wiab Water Innovation Ab | Acetic acid and hypochlorous acid compositions for treatment of skin trauma |
US11364263B2 (en) | 2012-02-17 | 2022-06-21 | Wiab Wafer Innovation Ab | Compositions and methods for aerodigestive treatment |
ES2966295T3 (es) | 2012-02-17 | 2024-04-19 | Wiab Water Innovation Ab | Composiciones de ácido hipocloroso (HOCl) y métodos de fabricación de las mismas |
US11672825B2 (en) | 2012-02-17 | 2023-06-13 | Wiab Water Innovation Ab | Acetic acid and hypochlorous acid compositions for treatment of biofilms and wound care |
US10675299B2 (en) | 2012-02-17 | 2020-06-09 | Wiab Water Innovation Ab | Hand disinfectant |
US20150044144A1 (en) * | 2012-03-06 | 2015-02-12 | Raymat Materials, Inc. | Disinfectant solution |
MX2015016057A (es) | 2013-05-22 | 2016-03-21 | Oculus Innovative Sciences Inc | Solucion estabilizada de acido hipocloroso y uso de la misma. |
JP2016535044A (ja) * | 2013-10-29 | 2016-11-10 | ハイポ−ストリーム・リミテッド | 次亜塩素酸ナトリウムを含む抗炎症溶液 |
KR20190028712A (ko) * | 2016-06-22 | 2019-03-19 | 브리오테크 인코포레이티드 | 비완충 차아할로스산 조성물에 의한 고 내성 감염성 미생물 및 단백질의 불활성화 |
US11357876B2 (en) * | 2016-09-30 | 2022-06-14 | Eastern Technologies, Inc. | Compositions and methods of making and using the same |
CN108926492A (zh) * | 2017-05-25 | 2018-12-04 | 北京甲护生物科技有限公司 | 一种酸性氧化电位水消毒湿巾的制备方法 |
US11116791B2 (en) * | 2018-04-25 | 2021-09-14 | Rdg Holdings, Inc. | Compositions and methods for the treatment of cystic fibrosis |
FR3089520B1 (fr) * | 2018-12-07 | 2021-09-17 | Commissariat Energie Atomique | Pâte de decontamination et procede de decontamination d’un substrat en un materiau solide utilisant cette pâte |
IT202000013996A1 (it) * | 2020-06-25 | 2021-12-25 | Mitsa S R L | Metodo ed apparato per la purificazione e sterilizzazione dell’acqua |
CN112076215A (zh) * | 2020-08-18 | 2020-12-15 | 珠海市索利达医疗器械有限公司 | 一种改善生殖道微生态的抗菌组合物及其应用 |
AU2021332278A1 (en) * | 2020-08-25 | 2023-05-11 | Collidion, Inc. | Methods and uses of producing compositions stably comprising free available chlorine species and peroxides |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3499844A (en) * | 1967-08-21 | 1970-03-10 | Fmc Corp | Method of preparing an aqueous hydrogen peroxide gel |
US4236992A (en) * | 1979-08-06 | 1980-12-02 | Themy Constantinos D | High voltage electrolytic cell |
US4574084A (en) * | 1983-02-25 | 1986-03-04 | Peter Berger | Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof |
US4670254A (en) * | 1983-12-09 | 1987-06-02 | Toko Yakuhin Industry Co., Ltd. | Gel preparations for topical application of diclofenac sodium |
US4615937A (en) | 1985-09-05 | 1986-10-07 | The James River Corporation | Antimicrobially active, non-woven web used in a wet wiper |
US4666621A (en) | 1986-04-02 | 1987-05-19 | Sterling Drug Inc. | Pre-moistened, streak-free, lint-free hard surface wiping article |
US4781974A (en) | 1986-04-23 | 1988-11-01 | James River Corporation | Antimicrobially active wet wiper |
US5388571A (en) | 1987-07-17 | 1995-02-14 | Roberts; Josephine A. | Positive-pressure ventilator system with controlled access for nebulizer component servicing |
FI82808C (fi) | 1987-12-31 | 1991-04-25 | Etelae Haemeen Keuhkovammayhdi | Ultraljudfinfoerdelningsanordning. |
DE3929411A1 (de) * | 1988-09-22 | 1990-03-29 | Siegfried Natterer | Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung |
JPH03176022A (ja) * | 1989-12-04 | 1991-07-31 | Olympus Optical Co Ltd | 内視鏡用洗浄消毒装置 |
US5622848A (en) | 1990-05-23 | 1997-04-22 | Medical Discoveries, Inc. | Electrically hydrolyzed salines as microbiocides for in vitro treatment of contaminated fluids containing blood |
US5334383A (en) | 1990-05-23 | 1994-08-02 | Medical Discoveries, Inc. | Electrically hydrolyzed salines as in vivo microbicides for treatment of cardiomyopathy and multiple sclerosis |
DE69218901T2 (de) | 1991-12-10 | 1997-07-17 | Tdk Corp | Ultraschallzerstäuber |
US5287847A (en) | 1992-07-24 | 1994-02-22 | Vortran Medical Technology, Inc. | Universal nebulizer |
GB9227020D0 (en) * | 1992-12-24 | 1993-02-17 | Solvay Interox Ltd | Microbicidual compositions |
ATE214575T1 (de) | 1993-06-29 | 2002-04-15 | Ponwell Entpr Ltd | Spender |
KR100209843B1 (ko) | 1994-11-09 | 1999-07-15 | 데이비드 엠 모이어 | 지질중수 유화액으로 처리된 세정용 티슈 |
FR2740335B1 (fr) * | 1995-10-26 | 1997-12-19 | Oreal | Utilisation de sel de lanthanide, de lithium, d'etain, de zinc, de manganese ou d'yttrium comme antagoniste de substance p |
JPH09157173A (ja) * | 1995-11-02 | 1997-06-17 | Asahi Glass Eng Kk | ヒドロキシラジカル含有酸性水 |
CA2253357C (en) | 1996-04-30 | 2002-08-06 | The Procter & Gamble Company | Cleaning articles treated with a high internal phase inverse emulsion |
US6028018A (en) | 1996-07-24 | 2000-02-22 | Kimberly-Clark Worldwide, Inc. | Wet wipes with improved softness |
US5908707A (en) | 1996-12-05 | 1999-06-01 | The Procter & Gamble Company | Cleaning articles comprising a high internal phase inverse emulsion and a carrier with controlled absorbency |
JP5000037B2 (ja) * | 1997-10-10 | 2012-08-15 | ピュア バイオサイエンス | 殺菌剤 |
JPH11269686A (ja) * | 1998-03-18 | 1999-10-05 | Permelec Electrode Ltd | 過酸化水素の製造方法及び過酸化水素製造用電解槽 |
JP2000015263A (ja) * | 1998-07-07 | 2000-01-18 | Kinosui Kenkyusho:Kk | 電解アルカリ殺菌水およびその製造装置 |
US20030126710A1 (en) | 1998-11-09 | 2003-07-10 | Policicchio Nicola John | Cleaning composition, pad, wipe, implement, and system and method of use thereof |
SE9902627D0 (sv) | 1999-07-08 | 1999-07-08 | Siemens Elema Ab | Medical nebulizer |
GB2355190B (en) * | 1999-08-23 | 2004-07-28 | Sterilox Medical | Improvements in or relating to sterilising preparations |
JP2001139477A (ja) | 1999-11-17 | 2001-05-22 | Coherent Technology:Kk | 創傷部位の組織細胞増殖促進液 |
US6340663B1 (en) | 1999-11-24 | 2002-01-22 | The Clorox Company | Cleaning wipes |
US6387383B1 (en) * | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
JP2002145787A (ja) * | 2000-11-02 | 2002-05-22 | Kanebo Ltd | 外用剤 |
US6586385B1 (en) | 2001-11-13 | 2003-07-01 | Colgate-Palmolive Co. | Cleaning wipe |
US6624135B2 (en) | 2001-11-26 | 2003-09-23 | S.C. Johnson & Son, Inc. | Cleaning sheet |
EP1461474B1 (en) | 2001-12-05 | 2011-11-30 | Oculus Innovative Sciences, Inc. | Method and apparatus for producing negative and positive oxidative reductive potential (orp) water |
JP2005058848A (ja) * | 2003-08-08 | 2005-03-10 | Spring:Kk | 洗浄・消毒・創傷治癒に用いられる水の製造方法、その製造装置、及び洗浄・消毒・創傷治癒に用いられる水 |
-
2004
- 2004-12-30 MX MXPA05009960A patent/MXPA05009960A/es active IP Right Grant
- 2004-12-30 WO PCT/US2004/043961 patent/WO2005065383A2/en active Application Filing
- 2004-12-30 AU AU2004311432A patent/AU2004311432A1/en not_active Abandoned
- 2004-12-30 EP EP04815950A patent/EP1702161A2/en not_active Ceased
- 2004-12-30 EP EP17155148.4A patent/EP3205358A1/en not_active Withdrawn
- 2004-12-30 JP JP2006547576A patent/JP5528657B2/ja active Active
- 2004-12-30 CA CA2553943A patent/CA2553943C/en not_active Expired - Fee Related
- 2004-12-30 KR KR1020067015435A patent/KR101249639B1/ko active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2790976C1 (ru) * | 2021-12-07 | 2023-03-01 | Государственное Бюджетное Образовательное Учреждения Высшего Образования "Уральский Государственный Аграрный Университет" (ФГБОУ ВО Уральский ГАУ) | Способ содержания служебных собак |
Also Published As
Publication number | Publication date |
---|---|
CA2553943C (en) | 2014-02-11 |
CA2553943A1 (en) | 2005-07-21 |
KR20070015123A (ko) | 2007-02-01 |
JP2007517064A (ja) | 2007-06-28 |
EP3205358A1 (en) | 2017-08-16 |
AU2004311432A1 (en) | 2005-07-21 |
EP1702161A2 (en) | 2006-09-20 |
MXPA05009960A (es) | 2006-05-25 |
WO2005065383A3 (en) | 2006-04-27 |
WO2005065383A2 (en) | 2005-07-21 |
KR101249639B1 (ko) | 2013-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5528657B2 (ja) | 酸化還元電位水溶液並びにその製造方法および使用方法 | |
US10016455B2 (en) | Method of preventing or treating influenza with oxidative reductive potential water solution | |
AU2011200390B2 (en) | Oxidative reductive potential water solution, processes for producing same and methods of using the same | |
JP5816405B2 (ja) | 酸化還元電位水溶液を使用する第二度及び第三度熱傷の治療方法 | |
JP5907645B2 (ja) | 歯科用途における酸化還元電位水溶液の使用法 | |
JP5723084B2 (ja) | 酸化還元電位水溶液を用いた副鼻腔炎の予防または治療方法 | |
CN101163492B (zh) | 利用氧化还原电位水溶液治疗2度和3度烧伤的方法 | |
AU2012241151B2 (en) | Method of using oxidative reductive potential water solution in dental applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071228 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110906 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111202 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120306 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130124 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130218 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130423 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130701 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130708 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131023 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140220 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140311 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140416 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5528657 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |